Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
36.20
-0.17 (-0.47%)
At close: May 13, 2025, 4:00 PM
36.50
+0.30 (0.83%)
Pre-market: May 14, 2025, 8:39 AM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,372 employees as of December 31, 2024. The number of employees increased by 58 or 4.41% compared to the previous year.
Employees
1,372
Change (1Y)
58
Growth (1Y)
4.41%
Revenue / Employee
$1,627,821
Profits / Employee
-$181,041
Market Cap
3.56B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,372 | 58 | 4.41% |
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SRPT News
- 23 hours ago - Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy - Business Wire
- 5 days ago - Top 3 Health Care Stocks That Are Preparing To Pump This Quarter - Benzinga
- 5 days ago - Sarepta Therapeutics to Present at the BofA Securities Health Care Conference - Business Wire
- 6 days ago - Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating - Seeking Alpha
- 6 days ago - Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up - Benzinga
- 6 days ago - Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade - Seeking Alpha
- 6 days ago - Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results - Benzinga
- 7 days ago - Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga